Precipio, Inc. Common Stock
PRPOPrecipio, Inc. is a biotechnology company specializing in diagnostic and testing services for cancer and infectious diseases. It develops and offers cutting-edge laboratory techniques, including oncology diagnostics and pathogen testing, aimed at improving patient outcomes through innovative and high-quality testing solutions.
Company News
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced significant balance sheet improvements by repaying a $1.1 million advance from Change Healthcare and completing the exercise of all financial warrants issued in 2023. The company now maintains a nearly debt-free balance sheet with only an $80,000 Connecticut state loan r...
Precipio conducted a comprehensive study with Memorial Sloan Kettering Cancer Center, evaluating their BCR::ABL1 assay using 895 patient samples. The study demonstrated superior performance and positive impacts on patient care and laboratory workflows.
Specialty cancer diagnostics company Precipio will host its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET, providing updates on its core businesses and diagnostic technologies.
Precipio reported Q2-2025 revenues of $5.7M, a 27% year-over-year increase, with improvements in both Products and Pathology Services divisions. The company expects to end the year cash flow positive and debt-free, driven by revenue growth and cost management.
Precipio has modified its warrant exercise structure, reducing potential share dilution and receiving approximately $1.2M in cash by changing the exercise method for 300,000 warrants.
